Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer

Jiheum Paek, Maria Lee, Eun Ji Nam, Sang Wun Kim, YoungTae Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: The aim of this study was to confirm the expression of high mobility group box 1 (HMGB1) in patients with epithelial ovarian cancer (EOC) and to evaluate the prognostic significance of HMGB1. Methods: A total of 74 patients with EOC comprised our cohort. Retrospectively collected tissue microarray from EOC patients treated with debulking surgery followed by taxane and platinum chemotherapy were analyzed for evaluation of the prognostic significance of HMGB1. Expression of HMGB1 was assessed by immunohistochemistry. Results: The positive staining was detected in 80 % of EOC patients and the rate of high HMGB1 expression was 42 %. In advanced stage, patients with high HMGB1 expression showed a poorer prognosis than low HMGB1 expression group [median progression-free survival (PFS), 10.8 vs. 21.7 months, P = 0.005]. High HMGB1 expression was an independent predictor for PFS (P = 0.024). Conclusions: HMGB1 expression is expected as a promising biomarker for EOC and further studies are needed to assess potential roles in EOC.

Original languageEnglish
Pages (from-to)645-650
Number of pages6
JournalArchives of Gynecology and Obstetrics
Volume293
Issue number3
DOIs
Publication statusPublished - 2016 Mar 1

Fingerprint

HMGB1 Protein
Disease-Free Survival
Platinum
Ovarian epithelial cancer
Biomarkers
Immunohistochemistry
Staining and Labeling
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynaecology

Cite this

Paek, Jiheum ; Lee, Maria ; Nam, Eun Ji ; Kim, Sang Wun ; Kim, YoungTae. / Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer. In: Archives of Gynecology and Obstetrics. 2016 ; Vol. 293, No. 3. pp. 645-650.
@article{53743743be064317985619a35505f8f5,
title = "Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer",
abstract = "Purpose: The aim of this study was to confirm the expression of high mobility group box 1 (HMGB1) in patients with epithelial ovarian cancer (EOC) and to evaluate the prognostic significance of HMGB1. Methods: A total of 74 patients with EOC comprised our cohort. Retrospectively collected tissue microarray from EOC patients treated with debulking surgery followed by taxane and platinum chemotherapy were analyzed for evaluation of the prognostic significance of HMGB1. Expression of HMGB1 was assessed by immunohistochemistry. Results: The positive staining was detected in 80 {\%} of EOC patients and the rate of high HMGB1 expression was 42 {\%}. In advanced stage, patients with high HMGB1 expression showed a poorer prognosis than low HMGB1 expression group [median progression-free survival (PFS), 10.8 vs. 21.7 months, P = 0.005]. High HMGB1 expression was an independent predictor for PFS (P = 0.024). Conclusions: HMGB1 expression is expected as a promising biomarker for EOC and further studies are needed to assess potential roles in EOC.",
author = "Jiheum Paek and Maria Lee and Nam, {Eun Ji} and Kim, {Sang Wun} and YoungTae Kim",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00404-015-3864-1",
language = "English",
volume = "293",
pages = "645--650",
journal = "Archives of Gynecology and Obstetrics",
issn = "0932-0067",
publisher = "Springer Verlag",
number = "3",

}

Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer. / Paek, Jiheum; Lee, Maria; Nam, Eun Ji; Kim, Sang Wun; Kim, YoungTae.

In: Archives of Gynecology and Obstetrics, Vol. 293, No. 3, 01.03.2016, p. 645-650.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer

AU - Paek, Jiheum

AU - Lee, Maria

AU - Nam, Eun Ji

AU - Kim, Sang Wun

AU - Kim, YoungTae

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose: The aim of this study was to confirm the expression of high mobility group box 1 (HMGB1) in patients with epithelial ovarian cancer (EOC) and to evaluate the prognostic significance of HMGB1. Methods: A total of 74 patients with EOC comprised our cohort. Retrospectively collected tissue microarray from EOC patients treated with debulking surgery followed by taxane and platinum chemotherapy were analyzed for evaluation of the prognostic significance of HMGB1. Expression of HMGB1 was assessed by immunohistochemistry. Results: The positive staining was detected in 80 % of EOC patients and the rate of high HMGB1 expression was 42 %. In advanced stage, patients with high HMGB1 expression showed a poorer prognosis than low HMGB1 expression group [median progression-free survival (PFS), 10.8 vs. 21.7 months, P = 0.005]. High HMGB1 expression was an independent predictor for PFS (P = 0.024). Conclusions: HMGB1 expression is expected as a promising biomarker for EOC and further studies are needed to assess potential roles in EOC.

AB - Purpose: The aim of this study was to confirm the expression of high mobility group box 1 (HMGB1) in patients with epithelial ovarian cancer (EOC) and to evaluate the prognostic significance of HMGB1. Methods: A total of 74 patients with EOC comprised our cohort. Retrospectively collected tissue microarray from EOC patients treated with debulking surgery followed by taxane and platinum chemotherapy were analyzed for evaluation of the prognostic significance of HMGB1. Expression of HMGB1 was assessed by immunohistochemistry. Results: The positive staining was detected in 80 % of EOC patients and the rate of high HMGB1 expression was 42 %. In advanced stage, patients with high HMGB1 expression showed a poorer prognosis than low HMGB1 expression group [median progression-free survival (PFS), 10.8 vs. 21.7 months, P = 0.005]. High HMGB1 expression was an independent predictor for PFS (P = 0.024). Conclusions: HMGB1 expression is expected as a promising biomarker for EOC and further studies are needed to assess potential roles in EOC.

UR - http://www.scopus.com/inward/record.url?scp=84958778210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958778210&partnerID=8YFLogxK

U2 - 10.1007/s00404-015-3864-1

DO - 10.1007/s00404-015-3864-1

M3 - Article

VL - 293

SP - 645

EP - 650

JO - Archives of Gynecology and Obstetrics

JF - Archives of Gynecology and Obstetrics

SN - 0932-0067

IS - 3

ER -